593 related articles for article (PubMed ID: 16877724)
1. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Hollenstein J; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
J Clin Oncol; 2006 Aug; 24(22):3576-82. PubMed ID: 16877724
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Madalinska JB; Hollenstein J; Bleiker E; van Beurden M; Valdimarsdottir HB; Massuger LF; Gaarenstroom KN; Mourits MJ; Verheijen RH; van Dorst EB; van der Putten H; van der Velden K; Boonstra H; Aaronson NK
J Clin Oncol; 2005 Oct; 23(28):6890-8. PubMed ID: 16129845
[TBL] [Abstract][Full Text] [Related]
3. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.
Benshushan A; Rojansky N; Chaviv M; Arbel-Alon S; Benmeir A; Imbar T; Brzezinski A
Climacteric; 2009 Oct; 12(5):404-9. PubMed ID: 19479488
[TBL] [Abstract][Full Text] [Related]
4. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
Madalinska JB; van Beurden M; Bleiker EM; Valdimarsdottir HB; Lubsen-Brandsma L; Massuger LF; Mourits MJ; Gaarenstroom KN; van Dorst EB; van der Putten H; Boonstra H; Aaronson NK
J Clin Oncol; 2007 Jan; 25(3):301-7. PubMed ID: 17235045
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
Vermeulen RFM; Beurden MV; Kieffer JM; Bleiker EMA; Valdimarsdottir HB; Massuger LFAG; Mourits MJE; Gaarenstroom KN; van Dorst EBL; van der Putten HWHM; Aaronson NK
Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
[TBL] [Abstract][Full Text] [Related]
7. The influence of premenopausal hormones on severity of climacteric symptoms and use of HRT.
Fentiman IS; Allen D; Wheeler M; Rymer J
Climacteric; 2006 Apr; 9(2):135-45. PubMed ID: 16698660
[TBL] [Abstract][Full Text] [Related]
8. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study.
Li C; Samsioe G; Lidfelt J; Nerbrand C; Agardh CD;
Menopause; 2000; 7(4):273-81. PubMed ID: 10914621
[TBL] [Abstract][Full Text] [Related]
9. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.
Finch A; Narod SA
Maturitas; 2011 Nov; 70(3):261-5. PubMed ID: 21893388
[TBL] [Abstract][Full Text] [Related]
10. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
12. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance.
Oddens BJ; Boulet MJ
Obstet Gynecol; 1997 Aug; 90(2):269-77. PubMed ID: 9241307
[TBL] [Abstract][Full Text] [Related]
14. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
[TBL] [Abstract][Full Text] [Related]
15. Thoughts on individualizing hormone replacement therapy based on the postmenopausal health disparities study data.
Gavaler JS
J Womens Health (Larchmt); 2003 Oct; 12(8):757-68. PubMed ID: 14588126
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with climacteric symptoms and the use of hormone replacement therapy.
Stadberg E; Mattsson LA; Milsom I
Acta Obstet Gynecol Scand; 2000 Apr; 79(4):286-92. PubMed ID: 10746844
[TBL] [Abstract][Full Text] [Related]
17. Use of hormone replacement therapy by menopausal women in six family-practice teaching clinics in Israel.
Vinker S; Kaplan B; Yaphe J; Cohen O; Shumla V; Shapira G; Shofty I; Kitai E
Climacteric; 2003 Mar; 6(1):75-80. PubMed ID: 12725667
[TBL] [Abstract][Full Text] [Related]
18. Type of menopause, patterns of hormone therapy use, and hot flashes.
Gallicchio L; Whiteman MK; Tomic D; Miller KP; Langenberg P; Flaws JA
Fertil Steril; 2006 May; 85(5):1432-40. PubMed ID: 16566933
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
Windler E; Zyriax BC; Eidenmüller B; Boeing H
Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
[TBL] [Abstract][Full Text] [Related]
20. Options for hormone therapy in women who have had a hysterectomy.
Haney AF; Wild RA
Menopause; 2007; 14(3 Pt 2):592-7; quiz 598-9. PubMed ID: 17476150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
